G6PD and ovarian cancer: In this view, a liposomal formulation of cisplatin was studied for prolonged pharmacokinetics of the drug in combination with 6-AN, an inhibitor of the enzyme G6PD (the rate-limiting step of the PPP), to restore the sensitivity of resistant cisplatin ovarian cancer cells [48].